News 30.05.2017 Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 study, the efficacy and safety...
Internal events
Event date: 13.06.2017
The TECOmedical Team would like to invite you to discuss the options and opportunities of Biomarkers as an important tool in research projects and during drug discovery.
- Drug induced toxicity
- Safety and efficacy testing
- Cell death of anti-cancer drug treatment
- Biocompatibility
- Readycell for permeability – transporter and toxicity testing
June 13...
News 19.05.2017 Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding experience in the life science sector. Virometix plans to use the new...
News 12.05.2017 Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., co-founder of the company, as Chief Executive Officer and to nominate him to become a member of...
News 26.01.2017 Virometix today announced the appointment of Dr. Pierre A. Morgon, PharmD, LL.M., MBA as Chairman and Dr. Isaac Kobrin as independent member to its Board of Directors. In addition, the company announced the nomination of Emmanuel Savioz, MBA as new Chief Financial Officer. With these appointments Virometix is taking further...